Sionna Therapeutics, Inc. - 10-Q Filing

Sionna Therapeutics reports Q3 2026 financial results including research and development expenses and stock-based compensation details.

SEC EDGAR ·

Tickers: $SION

Read the full article at SEC EDGAR

More Regulatory news